太极集团子公司司美格鲁肽注射液获临床试验批件

Core Viewpoint - Taiji Group's subsidiary Fuling Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection for type 2 diabetes [1] Group 1: Company Developments - Fuling Pharmaceutical, a wholly-owned subsidiary of Taiji Group, has been granted a Clinical Trial Approval Notice for Semaglutide injection [1] - The clinical trials will focus on the indication of type 2 diabetes, specifically for blood sugar control in adult patients [1] - The total research and development investment in this project amounts to approximately 44.1834 million yuan [1] Group 2: Product Information - Semaglutide injection is classified as a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist [1] - It is intended for use in adult patients with type 2 diabetes to manage blood sugar levels and reduce the risk of major cardiovascular adverse events in those with cardiovascular disease [1]